Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets
- 8 October 2024
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (10) , e0053324
Abstract
Oxazolidinones (linezolid and tedizolid) adverse reactions include thrombocytopenia, the mechanism of which is still largely unknown. In cultured cells, oxazolidinones impair mitochondrial protein synthesis and oxidative metabolism. As mitochondrial activity is essential for megakaryocyte differentiation and maturation into platelets, we examined whether oxazolidinones impair these processes ex vivo and alter, in parallel, the activity of mitochondrial cytochrome c -oxidase (CYTOX; enzyme partly encoded by the mitochondrial genome) and cell morphology. Human CD34+ cells were isolated, incubated with cytokines (up to 14 days) and clinically relevant oxazolidinone concentrations or in control conditions, and used for (i) clonogenic assays [counting of megakaryocyte (CFU-Mk), granulocyte-monocyte (CFU-GM), burst-forming unit-erythroid (BFU-E) colonies]; (ii) the measure of the expression of megakaryocyte surface antigens (CD34 to CD41 and CD42); (iii) counting of proplatelets; (iv) the measurement of CYTOX activity; and (v) cell morphology (optic and electron microscopy). Oxazolidinones caused a significant decrease in BFU-E but not CFU-Mk or CFU-GM colonies. Yet, the megakaryocytic lineage was markedly affected, with a decreased differentiation of CD34+ into CD41+/CD42+ cells, an abolition of proplatelet formation and striking decrease in the numbers of large polylobulated nucleus megakaryocytes, with a complete loss of intracellular demarcation membrane system, disappearance of mitochondria, and suppression of CYTOX activity. These alterations were more marked in cells incubated with tedizolid than linezolid. These data suggest that oxazolidinones may induce thrombocytopenia by impairing megakaryocytic differentiation through mitochondrial dysfunction. Pharmacological interventions to prevent this toxicity might therefore be difficult as mitochondrial toxicity is most probably inherently linked to their antibacterial activity.Keywords
Funding Information
- Ludwig Institute for Cancer Research
- Stichting Tegen Kanker
- Salus Sanguinis
- Les avions de Sébastien
- Actions de Recherche Concertée (16/21-073)
- Wel research Institute Welbio (F 44/8/5 - MCF/UIG - 10955)
- Ligue Contre le Cancer
- Institut National Du Cancer (INCA-PLBIO-2015)
- Institut National de la Santé et de la Recherche Médicale
This publication has 38 references indexed in Scilit:
- Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting systemExpert Opinion on Drug Safety, 2021
- Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell linesInternational Journal of Antimicrobial Agents, 2019
- Thrombopoietin Metabolically Primes Hematopoietic Stem Cells to Megakaryocyte-Lineage DifferentiationCell Reports, 2018
- Megakaryocyte and polyploidizationExperimental Hematology, 2018
- Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomesExpert Opinion on Drug Safety, 2017
- ROS-mediated platelet generation: a microenvironment-dependent manner for megakaryocyte proliferation, differentiation, and maturationCell Death & Disease, 2013
- Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunctionJournal of Infection and Chemotherapy, 2011
- Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunctionInternational Journal of Antimicrobial Agents, 2010
- Ex Vivo Megakaryocyte Expansion and Platelet Production from Human Cord Blood Stem Cells2009
- The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human MitochondriaMolecular Cell, 2007